What is Vaxcyte, Inc.'s AFS securities?

Vaxcyte, Inc. (PCVX) reported AFS securities of $1B in Q1 2026.

How has Vaxcyte, Inc.'s AFS securities changed year-over-year?

Vaxcyte, Inc.'s AFS securities decreased by 21.5% year-over-year, from $1.28B to $1B.

Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.

ModernaMRNA

$2.25B-6.9%

Operating income-$345.9M-91.3%

Net income-$320.6M-128%

EPS (diluted)-$2.30-121%

Cash & equivalents$262.3M-24.7%

Total debt$116.3M+33.5%

Total equity$3.0B-6.4%

Total assets$3.3B-0.9%

Operating cash flow-$280.6M-68.8%

CapEx$2.1M-61.2%

Free cash flow-$282.7M-64.7%

Market cap$7.43B+72.0%

Enterprise value$7.28B+78.6%

Return on equity-30.6%+37.9pp

Debt / equity0×0.0×

Current ratio7.5×-10.2×

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Vaxcyte, Inc.'s AFS securities?: Vaxcyte, Inc. (PCVX) reported AFS securities of $1B in Q1 2026.
How has Vaxcyte, Inc.'s AFS securities changed year-over-year?: Vaxcyte, Inc.'s AFS securities decreased by 21.5% year-over-year, from $1.28B to $1B.
What does AFS securities mean?: Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.